Summary: Leucine oxidation and incorporation into pro teins were examined in the in vivo rat brain to determine rates and compartmentation of these processes for the purpose of structuring mathematical compartmental mod els for the noninvasive estimation of in vivo human cere bral protein synthesis rates (CPSR) using positron emis sion tomography (PET). Leucine specific activity (SA) in arterial plasma and intracellular free amino acids, leucyl tRNA, a-ketoisocaproic acid (KIC), and protein were de termined in whole brain of the adult rat during the first 35 min after intravenous bolus injection of L-[1-14C]leucine. Incorporation of leucine into proteins accounted for 90% of total brain radioactivity at 35 min. The lack of [14C]KIC buildup indicates that leucine oxidation in brain is transaminase limited. Characteristic specific activities were maximal between 0 to 2 min after bolus injection with subsequent decline following the pattern: plasma
leucine ;?: leucyl-tRNA = KIC > intracellular leucine. The time integral of leucine SA in plasma was about four times that of tissue leucine and twice those of leucyl tRNA and KIC, indicating the existence of free leucine, leucyl-tRNA, and KIC tissue compartments, communi cating directly with plasma, and separate secondary free leucine, leucyl-tRNA, and KIC tissue compartments orig inating in unlabeled leucine from proteolysis. Therefore, a relatively simple model configuration based on the key assumptions that (a) protein incorporation and catabolism proceed from a precursor pool communicating with the plasma space, and (b) leucine catabolism is transaminase limited is justified for the in vivo assessment of CPSR from exogenous leucine sources using PET in humans. Key Words: L-[1-14C]leucine-Leucyl-transfer RNA Tracer kinetic models-Protein synthesis rates-Leucine oxidation-Precursor pools.
analyses of carbon-I -labeled leucine in plasma and brain of an appropriate animal model, in order to identify and validate tracer kinetic modeling ap proaches (Hawkins et aI., 1987 (Hawkins et aI., , 1989 . Structuring and assumptions applied to the tracer kinetic mod els (Hawkins et al., , 1989 from biochemical data presented here will allow us to make accurate in vivo estimates of local brain reaction rates and kinetic rate constants when using noninvasive tracer techniques (Huang and Phelps, 1986; Sorenson and Phelps, 1987) . Accurate mea surement of in vivo protein synthesis using tracer techniques and PET can provide a method for as sessing alterations in local protein synthesis rates associated with such processes as development (Barra et aI., 1972; Chou and Johnson, 1972; Harris and Maas, 1974; Srivastava et aI., 1984) , regenera tion and repair in response to injury or disease (Yap and Spector, 1965; Bodsch et aI., 1986; Kiessling et aI., 1986) , plasticity (Sayavedra, 1977) , changes in duced by drugs and hormones (Carenzi and Casacci, 1977) , degenerative disorders, neoplastic lesions (Barrio et aI., 1985) , learning, and memory (Barondes, 1970; Robertson et aI., 1978; Schliebs et aI., 1985; Shashoua, 1985) .
Our goal in this work was to measure via direct tissue assay the parameters needed to determine in vivo brain protein synthesis rates (Sokoloff, 1986) : (a) the time-dependent amount of labeled product (protein) formed and (b) the integrated specific ac tivity (SA) of the precursor pool. Values obtained using this invasive approach would be compared to solutions to the compartmental model approach (Phelps et aI., 1984; Hawkins et aI., 1987 Hawkins et aI., , 1989 gen erated from easily measured external parameters, namely (a) input function (i.e., time course of the injected radiotracer in whole blood or plasma); (b) tissue response (i.e., measured amount of activity in the tissue); and (c) plasma substrate concentra tion. The accuracy of the model solution corre sponding to the measured value from direct tissue assay validates the model (Huang and Phelps, 1986; Sorenson and Phelps, 1987) . Moreover, physiologic conditions under which the model breaks down and ways to correct for these errors may also be as sessed.
The present in vivo study upon which a compart mental model was structured (Hawkins et aI., 1987 (Hawkins et aI., , 1989 was carried out in brains of normal awake adult rats using L-[ 1-14C]leucine as the tracer. Therefore, the results of the present study can be considered valid under normal physiologic conditions. Studies under other sets of conditions (i.e., abnormal states) should be validated. Advan tages for using carbon-l carboxyl-labeled leucine (Banker and Cotman, 197 1) for measuring in vivo cerebral protein synthesis rates with PET include the following: (a) Leucine can be efficiently and re producibly synthesized with a positron-label (car bon-II, 20.38 min half-life) at the carbon-l position (Barrio et aI., 1983a) . (b) It has a high blood-brain barrier (BBB) permeability. Only phenylalanine has a higher BBB permeability than leucine (Oldendorf, 197 1) . Therefore, after administration of radiola beled leucine, sufficient activity is transported and retained in tissue to provide acceptable statistical accuracy for image reconstruction and for parame ter estimation with the tracer kinetic model (Barrio et aI., 1982; Phelps et aI., 1985) . (c) After intrave nous injection, leucine shows a fast clearance in blood to a low plasma concentration to reduce the J Cereb Blood Flow Metab, Vol. 9, No . 4, 1989 effect of blood volume in tissue data and to reduce delays in approaching near steady states for the tracer in tissue (Phelps et aI., 1984 (Phelps et aI., , 1985 . (d) Car bon-I-labeled leucine provides an approach that can account for or eliminate the metabolic pathway for the labeled amino acid in cerebral tissues (Banker and Cotman, 197 1; Phelps et aI., 1984) (Fig. 1) .
Accurate determination of in vivo protein synthe sis rates requires retention of the radioactive prod uct in a large and/or slow turnover pool of protein to provide an environment where the end product is trapped. Consistent with this requirement, the half life of mixed brain proteins was found to be close to 4 days (Garlick and Marshall, 1972; Parks et aI., 1976) . Worthy of consideration is the fact that in corporation of L-Ieucine into brain proteins in our study constituted a composite rate of protein syn thesis into many proteins (Campagnoni and Mahler, 1967; Autilio et aI., 1968; White et aI., 1972; Berke ley et aI., 1977; Marotta et aI., 198 1; Nowak et aI., 1984; Kler and Rosen, 1985) , in many cell types (Siegel et aI., 198 1) that make up the whole brain.
The purpose of the present paper is to (a) deter mine the rate of incorporation of leucine into brain proteins based on direct tissue measurements of leucyl-tRNA as the precursor; (b) establish the re lationship between the integrated precursor pool (leucyl-tRNA) SA and the easily measured inte grated plasma free leucine SA; (c) examine the re lationship between leucine oxidation and protein in- brain tissue. The scheme illustrates how 14C-labeled carbon-1 is eliminated at the decarboxylation step as 14C02 that dif fuses out of the tissue and is removed by cerebral blood flow. Therefore, at all times, KIC and CO2 are the only radioactivity labeled metabolites due to labeling at carbon-1 of leucine (see Fig. 7 and the Results section). LEU, leucine; lX-KG, lX-ketoglutaric acid; GLU, glutamic acid; KI C, lX-keto isocaproate ; NAD+, nicotinamide adenine dinucleotide; NADH, reduced form of NAD+; CoA, coenzyme A; BCAT, branched-chain amino acid transaminase; BCKD, branched chain keto acid dehydrogenase.
corporation fluxes and pools; and Cd) provide bio chemical data properly to structure and validate mathematical compartmental models to estimate rates of leucine incorporation into brain proteins in humans using easily measured external parameters and PET.
MATERIALS AND METHODS
Porcine kidney D-amino acid oxidase (EC 1.4.3.3), ca nine liver catalase (EC 1.11.1.6), and crude Escherichia coli aminoacyl-tRNA synthetase (EC ligase subclass 6.1.1) were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.). 4,5-Dimethoxy-l ,2-diaminobenzene (DDB) monohydrochloride was obtained from Dojindo Laboratories (Kumamoto, Japan), through American To kyo Kasei, Inc. (Tokyo, Japan). Substrates and cofactors were from Sigma Chemical Co. Low-pressure glass col umns and ion exchange resins were from Bio-Rad Labo ratories. Medium-pressure glass columns were from Om nifit Limited and advanced ion exchange celluloses were 
Experimental procedure and brain sampling
Male Sprague-Dawley rats (250-300 g) were supplied with food (Wayne Rodent Blox) and water ad libitum. Animals were anesthetized with 1.5% halothane for less than 20 min, during which time polyethylene cannulae were introduced into the femoral vein for administration of the radioactive amino acid, and into the femoral artery for collection of blood samples. After anesthesia, animals were wrapped with extra-fast-setting plaster bandages and taped to a piece of cardboard to prevent them from removing the cannulae yet allowing them to remain com fortable. Body temperature was maintained at 37°C. In jection of L-[1-14C]leucine into the femoral vein did not begin until 3 h after removal of the animal from anesthe sia to minimize the affect of halothane on brain protein synthetic rate (Ishii and Corbascio, 1971; Flaim et aI., 1983) .
A bolus injection of L-[ l-14C]leucine (50 !-LCi; 56 I1Cill1mol) in 0.5 ml (98% sterile water, 2% ethanol) was made over 10 s via venous cannula into the alert rat. Blood samples (200 !-LI) were collected at various times during the experimental period from the arterial cannula into heparin-coated microfuge tubes. Arterial plasma was rapidly separated and analyzed for total radioactivity as well as for radioactivity and mass of individual metabo lites. At 2 to 35 min after bolus injection, the alert rat was decapitated, and the whole brain removed and fixed in liquid nitrogen, the entire process taking less than 40 s using a standard decapitator. Decapitation, whole brain removal, and fixation in liquid nitrogen was reduced to less than lOs using a modified decapitator from the lab oratory of Dr. William Oldendorf, which concomitantly split the skull in half, facilitating more rapid removal of whole brain tissue (Ferrendeli et aI., 1972) . There was no significant difference in leucyl-tRNA SA determined by the 40 or 10 s fixation process. The same constancy in leucyl-tRNA SA values was found in heart tissue fixed in 40 or 2 s (Martin et aI., 1977) . In ancillary experiments, L-[2,3,4,5-3H]leucine (500 !-LCi i. v. bolus; 115 Ci/mmol) was administered to rats under the same experimental conditions to provide a lower tracer mass and a higher signal-to-noise ratio in tissue extracts as a check on ac curacy of results obtained with L-
Brain L-[1-14C]leucyl-tRNA was prepared using modi fications of previous procedures (Kirby, 1968; Yang and Novelli, 1971; Martin et aI., 1977; McKee et aI., 1978) . The ester bond between the amino acid and the 3' termi nus of tRNA in aminoacyl-tRNAs is very sensitive to heat and basic pH. So all isolation procedures were done at 4°C and pH 4.5 to stabilize the aminoacyl-tRNA (Lode mann et aI., 1970; Hentzen et aI., 1972) . The liquid nitro gen fixed whole brain was ground to a powder in liquid nitrogen and 1 g of dry ice. Brain powder was placed in a 250 ml flask and 18 ml of 0.25M NaCI, 10 mM MgClz, 1 mM NazEDTA, 10 mM sodium acetate, pH 4.5, 0.4 mg/ml of bentonite, and 18 ml of 80% liquified phenol were added and vigorously mixed for 1 h. The phenol suspension was centrifuged in a Beckman JA-21 rotor at 18,000 rpm (31,000 g) for 15 min. The aqueous layer (12 ml) was removed and rapidly chromatographed in a 1.5 x 5.0 cm DE52 DEAE cellulose column with 100% 0.25M NaCI, 10 mM MgClz, 1 mM NazEDTA, 10 mM sodium acetate, pH 4.5, and a flow rate of 4.0 mllmin. One minute fractions were collected with a Gilson Micro fractionator for a total volume of 60 ml. Free amino acids and protein were eluted in these fractions. The column solvent was switched to 0.70M NaCI, 10 mM MgClz, 1 mMNazEDTA, 10 mM sodium acetate, pH 4.5, and 0.7 min fractions collected for a total volume of 42 ml. Ami noacyl-tRNA was eluted with the higher salt concentra tion. A 1 ml aliquot of all fractions was counted for 14C to determine which were the peak fractions containing the desired aminoacyl-tRNA fraction. This isolation proce dure yielded greater than 80% recovery of L-[1-14C] leucine-tRNA standard added to nonradioactive brain powder.
L-[1-14C]leucyl-tRNA standard was synthesized ac cording to the procedure of Alexander et aI. (1985) using crude E. coli aminoacyl-tRNA synthetase (EC ligase sub class 6.1.1), Escherichia coli tRNA, and L-[1-14C]leucine.
Gel permeation high-performance liquid chromatogra phy (HPLC) analyses of peak fractions containing the aminoacyl-tRNA fraction indicated that all of the radio activity was associated with tRNA and not larger molec ular weight (>30,000 MW) nucleic acids (DNA or RNA) or free amino acids (Fig. 2) . Also indicated was that our preparation was highly pure (>95%) tRNA (Fig. 2, panel Al). Rapid separation of rRNA (1.l x 106 MW), tRNA (2.7 x 104 MW), and 14C-amino acid (1.2 x 10 2 MW) was accomplished in less than 26 min using gel permeation conditions (Fig. 3) .
Isolation of amino acids and tRNA from aminoacyl-tRNA
The aminoacyl-tRNA fraction was adjusted to pH 9.0 with O.4M sodium borate, pH 9.5 and incubated at 37°C for 90 min to deacylate the aminoacyl-tRNA (Hentzen et a!., 1972; Martin et a!., 1977) . This mixture was then lay ered onto a Centricon-30 ultrafiltration apparatus (30,000 MW cutoff ultrafiltration membrane) to separate the tRNA (retained by the membrane) from the deacylated amino acids (which pass freely through the membrane). More than 99% of radioactivity was recovered in the amino acid ultrafiltrate, which was analyzed by reversed- After phe nolization and separation of free amino acids, protein, and large molecular weight nucleic acids via DEAE cellulose col umn, soluble RNA was analyzed on TSK SWP, 7.5 x 75 mm precolumn; TSK G3000SW, 7.5 x 600 mm (lKB); 100% 0.25M NaCI, 10 mM MgCI2, 1 mM Na2EDTA, 10 mM sodium acetate, pH 4.5; flow rate of 1.3 ml/min; temperature of 22°C; UV ab sorbtion detector. Fractions were collected with a Gilson mi crofractionator and 14C was counted in a Beckman lS-335 liquid scintillation counter. (A1) Soluble RNA in whole rat brain 2 min after bolus injection of l-[1-14Cjleucine. (A2) 14C_ labeled soluble RNA in whole rat brain 2 min after bolus injection of l-[1-14Cjleucine. tRNA, transfer RNA. One hun dred percent of 14C radioactivity was released from tRNA as free amino acid leucine upon incubation at pH 9.0 and 37"C for 90 min. The specific activity of this released leucine was determined and plotted as aminoacyl-tRNA leucine specific activity (Fig. 8 ). Chromatography conditions were the same as in Fig. 2 . An on-line Berthold 506C Radioactivity Flow Monitor was used to detect 14C-amino acids. rRNA, ribosomal RNA.
phase HPLC using precolumn o-phthaldialdehyde (OPT) fluorescence derivatization (Lindroth and Mopper, 1979; Jones and Gilligan, 1983 ) and on-line fluorescence detec tion (Barrio et aI., 1986) . This HPLC technique can re solve and detect primary amines (e.g., amino acids and peptides) to subpicomole levels. HPLC analysis of amino acids released from tRNA revealed that all of the 14C activity was associated with leucine (Keen, 1988) .
Leucine specific activity in
]leucyl-tRNA SA was calculated by dividing the [14C]leucine dpm/ml in the aminoacyl-tRNA peak fraction by the nmol/ml of leucine determined by re versed-phase HPLC in the same fraction. The deacylated tRNA retentate was quantitated via A 2 60 nm measure ments (Gueron and Leroy, 1978 ) on a Cary model 219 UV -VIS spectrophotometer.
Specific activity of tissue free amino acids
The whole brain was removed from liquid nitrogen and homogenized in 8 ml of 5% HCI0 4 using a Brinkman Polytron. One milliliter of acid-soluble supernatant was removed after centrifugation and pH adjusted to 8.0 with 8N KOH. The sample was again centrifuged to separate the KCI0 4 precipitate and the aqueous phase was re moved and filtered through a 0.45 Il-m Millex-HV mem brane filter, which prepares it for reversed-phase HPLC using precolumn OPT fluorescence derivatization de scribed above (Barrio et a!., 1986) . In tandem to the on line fluorescence detector for OPT-amino acid quantita tion is a Berthold 506C radioactivity flow monitor, to measure 14C counts in the tissue acid-soluble fraction (Fig. 4, panel B) . Intracellular free leucine specific activ ity was calculated as dpm in the leucine HPLC radioac tivity peak divided by the nanomoles of leucine in the corresponding leucine fluorescence peak adjusted for the contribution of extracellular leucine. An extracellular space of 15% (Pardridge, 1983 ) and blood volume of 1.0% (Cremer and Seville, 1983) for rat brain in vivo was used for calculations.
Determination of leucine incorporation into protein
The protein pellet from the polytron-HCI0 4 homoge nate above was resuspended in water (8 m!) and centri fuged five consecutive times to remove any free amino acid associated with the protein precipitate. An aliquot of injection of L-[1-14Clleucine. Leucine specific activity was calculated as dpm in the leucine HPLC peak divided by nmol of leucine in the corresponding leucine fluorescence peak. These HPLC conditions were used to determine leucine-specific radioactivity in whole brain protein, aminoacyl-tRNA, and in plasma and intracellular free amino acid pools (Fig. 8 ).
the washed protein suspension was counted for 14C. An other aliquot was analyzed by the modified Lowry-Biuret method (Sigma Kit 690-A) to quantitate protein concen tration. A third aliquot of the washed protein suspension was hydrolyzed in a sealed ampule with 6N HCl at 100°C for 24 h. The protein hydrolysate was analyzed by reversed phase HPLC using precolumn OPT derivatization (Barrio et aI., 1986) to determine leucine percent composition in brain proteins. Leucine specific activity in total brain pro tein was calculated as dpm/mg of protein divided by !Lmol of leucine/mg of protein.
Specific activity of free leucine in arterial plasma
A total of 1.4 ml of 5% HCl0 4 was added to 100 !Ll of frozen arterial plasma (-20°C). The sample was vortexed and centrifuged to separate the protein. One milliliter of acid-soluble supernatant was removed, and the pH was adjusted to 8.0 with 8N KOH. This neutralized filtered sample was analyzed by reversed-phase HPLC using the precolumn OPT procedure with on-line fluorescence and radioactivity detectors connected to data acquisition computers as described for tissue free amino acid analysis (Fig. 4 , panel A). Arterial plasma free leucine specific activity was calculated as dpm in the leucine radioactive fraction divided by the nanomoles of leucine in the cor responding leucine fluorescence peak.
Measurement of tissue
1 4 C02 and
Tissue 14COZ and [1-14C]cx-ketoisocaproate e4C-KIC) were quantitated by modification of the Odessey and Goldberg (1979) method. Further description of the quan titative methods used are provided elsewhere (Keen et aI., manuscript in preparation).
Measurement of arterial blood and arterial plasma 1 4 C02 and 1 4 C_KIC
Fifty microliters of arterial blood or arterial plasma was immediately placed in a flask sealed with a gas-tight rub ber septum. Procedures for 14COZ and 14C-KIC quantita tion were similar to those described above.
Determination of tissue KIC concentration and specific activity
The brain tissue KIC concentration was quantitated us ing solid-phase extraction procedures (i.e., Bond Elut CIS columns) combined with DDB precolumn fluorescence derivatization HPLC (Hara et aI., 1985) . Intracellular KIC specific activity was calculated as dpm in the KIC fraction divided by the nmol of KIC in the corresponding KIC fluorescence peak adjusted for contribution of extra cellular KIC. Further description of the quantitative methods used are provided elsewhere (Keen et aI., manu script in preparation).
RESULTS

Arterial plasma input function
An example of the arterial plasma input function after intravenous administration of a L_[1_14C]_ leucine bolus is shown in Fig. 5 , panel A. At 2 min after bolus injection, 76% of the arterial plasma ra dioactivity remained as unmodified leucine and 11 % was protein (Fig. 5, panel B) Labeled KIC peaked immediately in arterial plasma after bolus administration (at 10 s) and then decreased, while labeled CO2 rose slowly to a pla teau above the 14C-KIC after 5 min (Fig. 5, panel  B) . This demonstrated that net flux through the Values are percent of total standard activity in arterial plasma ± I SD; greater than 98% recovery of radioactive metabolites in all experiments was obtained; n = 3 for each value; standard activity values are plotted in branched-chain amino acid transaminase (BCAT) is much more rapid than net flux through the branched-chain keto acid dehydrogenase (BCKD) in peripheral tissues taken as a whole (Buse et aI., 1975; Pardridge et aI., 1980; Pardridge, 1983) . These results were even more dramatically observed In the arterial blood (Fig. 6 ).
Carbon-14 distribution in brain tissue
Kinetics of carbon-14 distribution in rat brain af ter L-[ 1_14C]leucine bolus injection are shown in Fig. 7 . The label entered the brain tissue very rap idly with a peak in total brain radioactivity between �5 min. At 5 min after the bolus, 14C02 tissue con centration was maximal (19.0% of total brain radio activity) and the remaining radioactivity almost evenly distributed between protein (35%) and free leucine (45%). Very little 14C-KIC (0.7%) was seen at 2 min, or at later time points. The lack of 14C-KIC buildup demonstrates that flux through BCKD is much more rapid than flux through BCAT in the in vivo brain (see the Discussion section). This is anal ogous to leucine metabolism in liver, which is trans- aminase limited (Crabb and Harris, 1978; Pardridge, 1983) . The amount of label in proteins when compared with those of leucine or metabolite pools is domi nant for times later than 10 min after intravenous bolus injection. Incorporation of leucine into pro teins accounts for 90% of the total brain radioactiv ity at 35 min (Fig. 7) , demonstrating unique reten tion of label in the end product (protein) with clear ance of precursor leucine and metabolites (background) from tissue. No significant 14COZ fix ation into labeled tricarboxylic acid (TCA) cycle in termediates and associated amino acids (BerI et aI., 1962; Folbergrova et aI., 1974) was detected.
KIC and fr ee amino acid concentrations Intracellular KIC concentration was determined to be 0.70 ± 0.06 f.1M in the brain, which is in close agreement to the level predicted by Pardridge (1983) , based on the Ke q of branched-chain amino acid transaminase. Leucine free amino acid level in brain tissue was 89.3 ± 15.9 f.1M and in arterial plasma was 177.5 ± 31.3 f.1M. This yields a leucine brain to plasma concentration ratio of approxi mately 0.50 (Table 2) . Relationship of leucyl-tRNA to extracellular and intracellular free leucine pools
The time course of whole brain leucine specific activity (SA) in leucyl-tRNA, arterial plasma and intracellular free amino acids, and protein is shown in Fig. 8 . Between 0 to 2 min after bolus injection, all SA measured reached a peak with subsequent decline, except for leucine SA in protein, which rose to a steady-state level indicative of leucine trapping and slow turnover of the protein pool. Characteristic leucine SA after bolus injection were plasma leucine;;: leucyl-tRNA > intracellular leu cine. The time integral of leucine SA in plasma was about four times that of tissue leucine and twice that of leucyl-tRNA (Table 3) , indicating the existence of free leucine and leucyl-tRNA tissue compart ments, communicating directly with plasma, and separate secondary free leucine and leucyl-tRNA tissue compartments composed of unlabeled leu- cine from proteolysis. In ancillary experiments, us ing the same experimental procedures and a bolus injection of L-[2,3,4,5-3H]leucine (500 /-LCi; 115 Ci/mmol) to provide lower tracer mass and a higher signal-to-noise ratio in tissue extracts, the same re lationship between plasma leucine and leucyl-tRNA SA was observed at 35 min after injection.
Relationship of intracellular KIC to leucyl-tRNA and extracellular and intracellular free leucine pools
The time course of tissue KIC SA was virtually identical to the time course of leucyl-tRNA SA (Fig .   8) . Moreover, the time integral of leucine SA in plasma was about twice that of the KIC SA curve (Table 3) , which suggests the existence of a KIC tissue compartment, communicating directly with plasma, and a separate secondary KIC tissue com partment originating from unlabeled leucine from proteolysis. The turnover time (Ilk) of the free leu cine tissue compartment in communication with plasma and feeding the KIC and leucyl-tRNA com partments is about 3. 0 min, determined from the relative exponential decay rates of tissue and plasma leucine SA data (Fig. 8) . Since the very small leucyl-tRNA and KIC compartments turn over within seconds (see below), their SA decay curves are indicative of the larger free leucine tissue compartment that feeds them.
Brain protein synthesis flux
Leucine flux into whole brain mixed proteins is calculated from the following general equation for the measurement of reaction rates with tracers (Sokoloff, 1986) : reaction rate = labeled product formed in time 0 to T (isotope effect (integrated SA correction factor) x of precursor)
(I)
Since 14C as opposed to 1 2 C on carbon-l in L leucine will effect only an extremely small change in the rate of transport, aminoacylation of tRNA, and peptide bond formation reactions, the isotope effect correction factor in Eq. (I) can be considered to be a Values are areas under SA curves representing the integral from 0 to 35 min after injection (Fig.  8, panel B) .
b Values are ratios of the time integral of specific activities of the plasma leucine pool relative to those of the various tissue pools (from 0 to 35 min after injection) (Fig. 8). 1.0. Since protein turnover is very slow (i.e., half life is about 4 days for mixed brain proteins) (Gar lick and Marshall, 1972; Parks et aI., 1976) com pared with the experimental period, the labeled product formed e4C-Iabeled protein) can be consid ered fully and irreversibly trapped. The amount of labeled product formed (dpm of protein/g of brain) by 35 min after bolus injection was used (Fig. 7) in Eq. (1). In a single inlet system, the integrated spe cific activity of a compound precursor supplied ex clusively from an exogenous source is equal to the integrated specific activity of the exogenous source (the equal area rule) (Lassen and Perl, 1979) . Thus, the time integral of leucine SA in plasma (Table 3) represents the undiluted time integral of leucyl tRNA SA, and was used as the precursor to protein synthesis in Eq. (1). The rate of leucine incorpora tion [which we term the "cerebral protein synthesis rate" (CPSR)] from an exogenous leucine source was calculated to be 3.2 ± 0.59 nmol/min/g of brain (wet weight) in the conscious rat using the 35 min time integral.
Levels of total tRNA and leucyl-tRNA in brain
Quantitation of total tRNA isolated from brain (purity > 95%, see Fig. 2 , panel AI) by A260 (Gueron and Leroy, 1978) indicate that there was 20.02 nmol of total tRNNg of brain (wet weight). Determination of the leucyl-tRN A level was achieved by dividing the total dpm of leucyl-tRNA/g of brain by the specific activity, dpm/nmol, yielding 0.60 1 nmol of leucyl-tRNNg of brain (wet weight) ( Table 2 ). This is the actual amount of charged leucine tRN A in the normal in vivo brain, which is typically less by 20 to 50% than the fully charged state of the tRNA1eu isoacceptors (Barra et aI., 1972; Chou and Johnson, 1972; Smith and Santi, 1979) .
Brain leucyl-tRNA turnover time (precursor compartment turnover time) and half-life Plasma leucine is not the sole source of tissue leucyl-tRNA because the time integral of leucine SA in plasma was twice that of leucyl-tRNA (Table  3) , indicating a plasma-supplied leucyl-tRNA com partment, and a separate secondary leucyl-tRNA compartment of approximately equal size com posed of unlabeled leucine from proteolysis. Thus, leucyl-tRNA in communication with plasma is 0.300 nmol/g of brain or about one-half of the total tissue leucyl-tRNA pool ( Table 2) . Since the leucine in corporation rate from exogenous leucine source into brain protein is 3.2 nmol/min/g of brain and the leucyl-tRNA compartment in communication with plasma is 0.300 nmol/g of brain, simple division of the leucyl-tRNA compartment size by the leucine incorporation rate yields the precursor pool turn over time:
precursor compartment turnover time precursor compartment size
(2) rate of reactIOn According to this method, leucyl-tRNA turnover time (Ilk) is about 6 s (6.0 1 ± 1.4 1 s, n = 5) and leucyl-tRNA half-time (tIll = In 21k) is 4.2 ± 0.97 s.
Brain leucine oxidation flux
A rate constant (k) multiplied by an amount of a substance produces a flux (rate of reaction) (Soren son and :
Since the time integral of plasma leucine SA is twice that of KIC SA (Table 3) , tissue KIC like leucyl-tRNA above is represented by two compart ments, one in direct communication with plasma and an equal size KIC compartment composed of unlabeled leucine from proteolysis. Thus, the KIC in communication with plasma is 0.350 nmol/g of brain or approximately one-half of the total KIC pool size (Table 2 ). The rate constant for KIC oxi dation is expected to be similar to the rate constant for leucyl-tRNA incorporation into proteins be cause of the almost identical exponential decay curves of the oxidation and protein synthesis pre cursors (KIC and leucyl-tRNA SA data, respec tively) (Fig. 8) , assuming the rate of leucyl-tRNA breakdown is negligible (Lodemann et aI., 1970; Hentzen et aI., 1972) . As determined earlier, the rate constant of leucyl-tRNA incorporation to pro tein is 1O.6/min. This rate constant multiplied by the KIC compartment size of 0.350 nmol/g of brain yields a leucine oxidation flux of 3.7 ± 0.98 nmollmin/g of brain (wet weight) from exogenous leucine source. This yields a CPSR to catabolism ratio of 0.90 in the in vivo adult rat fed ad libitum.
DISCUSSION
This work was undertaken to provide useful bio chemical criteria for structuring the compartmental model approach for estimation of human cerebral protein synthesis rates with PET (Phelps et aI., 1984; Hawkins et aI., 1989) . Direct tissue and plasma measurements were made in the adult rat using L-[ 1-14C]leucine in order to obtain the neces sary biochemical information that would be ex tended to the L-[I-11C]leucine PET method in hu mans (Barrio et aI., 1985; Keen et aI., 1987) .
In order to measure the rate of a reaction from any quantitative radiotracer assay, the amount of labeled product formed and the integrated precur sor specific activity must be determined [Eq. (1)]. Leucyl-tRNA was used as the precursor to protein synthesis, since it is known that amino acid activa tion by incorporation into aminoacyl-tRNAs is the first step in protein synthesis in vivo (McKee et aI., 1978; Kelley et aI., 1984; Ward et aI., 1984) . Isola tion of aminoacyl-tRNA and determination of spe cific radioactivities of the attached amino acid are difficult tasks (Airhart et aI., 1974; Martin et aI., 1977; McKee et aI., 1978) . A combination of extrac tion from large amounts of tissue, high specific ac tivity tracers (i.e., 3H-Iabeled, 35S-labeled, or uni formly labeled 14C-amino acids), and detection to the nanomole level have been required in order to measure the specific activity of the amino acids re leased from the extremely small aminoacyl-tRNA pool (typically 5-20 nmol/g of tissue) (Regier and Kafatos, 1977; Samarel et aI., 198 1; Bodsch and Hossmann, 1983; Chikenji et aI., 1983) .
In addition to isolation of brain leucyl-tRNA, we were challenged by the determination of leucine flux through the oxidative pathway. The first two steps in branched-chain amino acid degradation are reversible transamination followed by irreversible oxidative decarboxylation of the resultant branched-chain a-ketoacids (Huston et aI., 1978; Barrio et aI., 1983b) (Fig. 1) . A reversed-phase pre-J Cereb Blood Flow Metab, Vol. 9, No. 4, 1989 column fluorescence derivatization HPLC tech nique for a-ketoacid assays had been recently re ported (Hara et aI., 1985) , which allowed the sub picomole sensitivity required to quantitate the very small KIC mass in a single brain. However, a con stant problem was that we were limited by the car rier free specific activity of the 14C nuclide at 60 f.LCi/f.Lmoi. In order to have reliable counting statis tics in tissue extracts, we injected from 30 to 50 f.LCi (0.50--0.80 f.Lmol) of L-[1-14C]leucine into rats con taining only 4.5 f.Lmol of leucine in their vascular space (tracer contained about 17% of the mass present in endogenous leucine plasma). However, no significant change in arterial plasma leucine con centration immediately before or after the L-[1-14C]leucine bolus injection was detected. Even at this dose maximum, we were hard pressed to detect radioactivity in leucyl-tRNA or KIC frac tions from single brain extracts (80% recovery of leucyl-tRNA and 70% recovery of KIC; see the Ma terials and Methods section) beyond 35 min after bolus injection of L-[l-14C]leucine. A single brain extract was used to allow for a direct comparison between intracellular KIC, intracellular leucine, and plasma leucine SA from the same animal. In a different experiment, a single brain was used to pro vide direct comparison of leucyl-tRNA and plasma leucine SA in the same animal. In ancillary experi ments, a 500 f.LCi bolus of the much higher specific activity L-[2,3,4,5-3H]leucine (115 Ci/mmol) was used that (a) lowered the mass of the injected tracer by almost 200-fold, and (b) increased the signal to-noise ratio in tissue extracts by 10-fold. In these experiments, the SA relationship between leucyl tRNA and plasma leucine was essentially identical to that determined with L-[ 1-14C]leucine.
The techniques reported here describe methods to determine leucyl-tRNA and KIC SA from less than 2 g of tissue (e.g., a single rat brain of approx imately 1.8 g) following a venous bolus injection of tracer L-[1-14C]leucine. To our knowledge, these studies are the first to measure tissue KIC SA di rectly (via solid phase extraction and reversed phase precolumn fluorescence derivatization HPLC). Schneible and co-workers (198 1) estimated intracellular KIC SA from 14C02 production in a cultured skeletal muscle preparation. KIC SA in perfusate of an in vivo hindlimb was measured by a more complicated and less sensitive gas chromatog raphy method (Huston et aI., 1978 (Huston et aI., , 1980 . Also, the present work appears to be the first report of the time course of leucyl-tRNA SA in brain tissue de termined from L-[1-14C]leucine. Reports of leucyl tRNA SA in brain (Bodsch and Hossmann, 1983) , heart (Everett et aI., 198 1; Martin et aI., 1977) , liver (Flaim et aI., 1982) , cultured skeletal muscle (Schneible et aI., 198 1; Low et aI., 1984; Schneible and Young, 1984) , lungs (Kelley et aI ., 1984) , and sea urchin eggs (Regier and Kafatos, 1977) were all determined using the higher specific activity tracer L-eH]leucine (60 Ci/mmol) .
For many reasons, carbon-I-labeled leucine was the tracer best suited for the PET method (Banker and Cotman, 197 1; Phelps et aI ., 1984) . Other car bon-I-labeled amino acids with high BBB perme ability (Oldendorf, 197 1) were synthesized and tested in our laboratories . L-[I-IlC]phenylalanine (Barrio et at ., 1983c; Phelps et at ., 1984) , L-[I-11C]tyrosine, and L-[1-11C]methionine were synthesized and tested in nonhuman primates and humans using PET. L-[ 1-14C]phenylalanine and L-[1 )4C]methionine incorporation into proteins was also examined autoradiographically in rats (Phelps et aI., 1984 (Phelps et aI., , 1985 Barrio et aI., 1983c; Barrio, 1986) . Even though initial studies indicated that these amino acids and leucine were qualitatively similar (Phelps et aI., 1984) , it is important to recognize that tyrosine (Friedman, 1982) , phenylalanine (Fried man, 1982) , and particularly methionine (Finkel stein, 1979; Diamondstone, 1982) have more com plicated metabolic pathways leading to delayed car bon-I oxidation . These alternate pathways of metabolism can lower or eliminate the specificity of the tracer technique for estimating CPSR, since the technique is capable of separating chemical reaction products only by differences in kinetic rates (Huang and Phelps, 1986) . Therefore, we used leucine to maximize clearance of precursor and metabolites (background) from tissue . The minor metabolites of leucine (KIC and bicarbonate) constituted less than 5% of total brain radioactivity at 35 min (Fig . 7) , demonstrating unique retention of label in the pro tein end product with minimum background noise . Jones and co-workers found similarly that leucine metabolites accounted for less than 3% of the ac tivity in rat brain at 45 min after injection (Jones et aI ., 1985) . In the present study, leucine also rapidly cleared from plasma to a low steady-state level (Fig .  5, panel A; Table 1 ), which reduces the effect of blood volume in tissue data and reduces delays in approaching near steady states for the tracer in tis sue (Phelps et aI., 1984 (Phelps et aI., , 1985 .
Methionine has also been labeled with carbon-II in the methyl position (Comar et aI ., 1976) . How ever, the methyl carbon of methionine is known to participate actively in metabolism (Diamondstone, 1982) , appearing in a number of nonprotein metab olites, namely S-adenosylmethionine, sarcosine, serine, glycine, phospholipids, and bicarbonate, which comprise 36% of the total activity in brain at 45 min after intravenous injection of methyl [14C]methionine (Jones et aI ., 1985) . a-methylation of acetylserotonin, 0-and N-methylation of cate cholamines, N-methylation of histamine, and non specific N-methylation of drugs and other biogenic amines are also very active processes in the central nervous system that use the methyl group of methi onine as the methyl donor via S-adenosylmethio nine and methyltransferases (Saavedra , 1978) . These data indicate that methionine has many side reactions that make it an unsuitable tracer for de termination of protein synthesis rates measured with PET or autoradiography . With the label in the methyl position, the end products of both incorpo ration into proteins and metabolism are retained in cerebral tissue (Bustany et aI ., 1983) . Therefore , PET measurements could only provide estimates of the sum of the two reaction pathways (Phelps et aI ., 1984; Barrio, 1986) .
Flux and compartmentation of leucine oxidation and incorporation into protein in the in vivo brain were examined in this work . First of all, there are two ultimate sources of leucine and other essential amino acids for cells, namely the extracellular space and endogenous protein degradation (Schneible et aI., 198 1) . Once in the cell, the only known metabolic pathways of leucine are the (a) anabolic (protein synthesis), (b) amphibolic (oxida tive degradation), and (c) proteolysis (protein deg radation) pathways (Diamondstone, 1982) . When injecting a bolus of labeled tracer intravenously, the time course of specific activity in plasma and tissue may be followed. If after a long time or when the SAs become negligible at time T (i.e., 35 min) the areas under the SA curves are not equal, then one may conclude that the plasma is not the sole source of the compound (the equal area rule) (Lassen and Perl, 1979) . In situ synthesis in tissue of the sub strate corresponding to the smaller area must be occurring. The equal area rule must always hold for a single inlet system (i.e., without dilution from other sources) (Lassen and Perl, 1979) .
In this work, the time integral of leucine SA in plasma is found to be about four times that of tissue leucine and twice that of leucyl-tRNA and KIC (Ta ble 3), indicating the existence of free leucine, leucyl-tRNA, and KIC tissue compartments, com municating directly with plasma, and separate sec ondary free leucine, leucyl-tRNA , and KIC tissue compartments composed of unlabeled leucine from protein degradation. Furthermore, the relative size of the unlabeled tissue compartments and labeled compartments are 3: 1 for free leucine, 1: 1 for leucyl-tRNA, and 1: 1 for KIC. Similar exponential decay rates of tissue leucine, tissue KIC, and leucyl-tRNA SA (Fig. 8) indicate that exogenous leucine oxidation and charging of tRNA are fed by a single leucine compartment in communication with plasma and with a fast turnover time for KIC and leucyl-tRNA pools (with a turnover time of ap proximately 3.0 min).
A model of leucine compartmentation consistent with our data is presented (Fig. 9) . The rate of leu cine incorporation into brain proteins (protein syn thesis flux), which is a measure of the exogenous utilization rate of plasma leucine, was determined to be 3.2 nmolfmin/g of brain based on the inte grated specific activity of plasma leucine, which represents the undiluted integrated specific activity PLASMA BBB of leucyl-tRNA [Eq. (1)]. These results agree well with the value of 3.3 nmollmin/g of CPSR, as deter mined from a compartmental modeling approach using arterial input functions, tissue response data, and plasma leucine concentration as discussed in detail in the accompanying paper (Hawkins et aI., 1989) .
Turnover times (1lk) of KIC and leucyl-tRNA compartments that communicate with plasma are fast and indistinguishable in magnitude, as illus trated by similar exponential decay patterns of their SA (Fig. 8) . Turnover time for leucyl-tRNA in whole rat brain was about 6 s, which is similar to findings in rat heart (Martin et aI., 1977) and in rat (
Biochemical compartmental model of leucine anabolic (protein synthesis) and amphibolic (oxidation) pathways in the brain consistent with the experimental data obtained on this work. This model describes the BBB bidirectional transport of leucine through the neutral amino acid transport, branching into oxidative or protein synthesis pathways from a common leucine compartment, in direct communication with plasma (L EUa compartment) or composed of unlabeled leucine from protein degradation (LEUb compartment), and clearance of CO2 from tissue to plasma. There appears to be little if any communication between the two free leucine compartments, as indicated by the dashed arrows. This can also be considered to be kinetically equivalent to the existence of a unique tissue leucine pool, in direct communication with plasma and in restricted communi cation with an intracellular leucine pool derived from protein proteolysis. The relative size of the unlabeled tissue compartments (box b) and labeled plasma supplied compartments (box a) are 3:1 for free leucine, 1:1 for leucyl-tRNA, and 1:1 for KIC. The rate of leucine incorporation into brain proteins from exogenous (plasma) leucine source is 3. 2 nmol/min/g (box a). Leucine oxidation flux from exogenous leucine source is 3.7 nmol/min (box a). The half-life of mixed brain proteins is 4 days (Garlick and Marshall, 1972; Parks et aI., 1976 ) (box a).
(1) Aminoacyl-tRNA synthetases plus ATP charge tRNAs with the respective amino acid.
Branched-chain amino acid transaminase (BCAT) catalyze reversible transamination of branched-chain amino acids (BCM) with a-ketoglutarate to form the respective a-ketoacid and L-glutamate . (3) Branched-chain ketoacid dehydrogenase (BCKD) cata lyzes oxidation of branched-chain a-ketoacids ; in the process, NAD + is reduced to NADH and CO2 is given off. BBB, blood-brain barrier ; LEU, leucine ; KIC, a-ketoisocaproic acid. Kinetic parameters derived from the mathematical compartmental model are provided in the accompanying paper (Hawkins et aI., 1989) .
liver for valyl-tRNA (Airhart et aI., 1974) . Using the transaminase-limited mathematical model, autora diography, and L-[1-14C]leucine, Smith and co workers (1980) estimated a leucine incorporation rate of 4.9 and 2.5 nmol/min/g for gray and white matter in rat brain, respectively, which brackets our findings for the whole brain. The approximately equal fluxes through oxidation and CPSR are sup ported by kinetic analysis of the rat data presented in Table 1 of the accompanying paper (Hawkins et aI., 1989) , with a CPSR to catabolism ratio of 1. 1. In addition, this result is consistent with what is re ported for central nervous system cells at a leucine medium concentration of 200 f.LM (Parks et aI., 1976) . Smith et aI. (1980) first proposed the transami nase-limited model for L-[1-14C]leucine in brain that is based on the fundamental assumption that (a) a single precursor pool in communication with plasma supplies the protein and metabolic compart ments ' and (b) that transaminase, not dehydroge nase, is the rate-limiting step in leucine oxidation. These assumptions greatly simplify the mathemati cal compartmental model used for autoradiography and PET for estimation of protein synthesis rates (Phelps et aI., 1984) . If brain leucine oxidation was in fact limited by dehydrogenase and not by the transaminase, three extra rate constants allowing for a pool of radioactivity in KIC, which can decay by reversible transamination back to leucine, by ox idation to CO2, or by efflux of KIC to plasma through the BBB, would need to be included in a more complex mathematical model (Pardridge, 1983) . To distinguish between transaminase-limited as opposed to dehydrogenase-limited pathways to leucine oxidation in brain, tissue kinetic studies of 14C_ KIC and 14C02 production after L-[ 1_14C]_ leucine bolus were carried out. In tissue kinetic studies, 14C-KIC remains very low (maximum is 0.7% of total brain radioactivity at 2 min) while 14C02 rose to a substantial peak at 5 min (19% of total brain radioactivity) (Fig. 7) . The lack of 14C_ KIC buildup suggests that flux through BCKD is much more rapid than the net flux through BCA T , indicating a transaminase-limited pathway in the brain. Given the tissue concentrations of leucine, a-ketoglutarate, and glutamate, KIC should reach a tissue level of 2-3 f.LM in order for the mass action ratio of the leucine transaminase reaction to be at equilibrium (Krebs, 1975) , if the oxidation flux were limited by BCKD. As shown in Table 4 , the actual tissue concentration of KIC is only 0.7 f.LM, so that equilibrium in the leucine transaminase system is not attained, which indicates that BCAT does not produce KIC as fast as it is consumed by BCKD. Ol-Ketoglutarate and L-glutamate data are from Folbergrova et al. (1974) and Cooper et al. (1979) , respectively. At equilibrium, the mass action ratio of the leucine transaminase system [Ol-K G)[LEU)/GLU)[KIC) is 0.65 (Krebs, 1975) . The ratio from measured brain tissue concentrations is 1. 8.
The biochemical data presented in this work con firm the transaminase-limited model in brain, which we have already used in preliminary PET studies (Phelps et aI., 1984 (Phelps et aI., , 1985 .
A priori, the transaminase-limited model of L-[1-14C]leucine in brain (Smith et aI., 1980; Par dridge, 1983) can be used with all carbon-I-labeled branched-chain amino acids [i.e., leucine, valine (Kirikae et aI., 1988) , and isoleucine]. Valine and isoleucine, like leucine, are essential amino acids (Diamondstone, 1982) that undergo first-step re versible transamination and second-step irrevers ible oxidative decarboxylation via the same BCAT and BCKD enzymes as leucine ( Fig. 1) (Huston et aI., 1978; Barrio et aI., 1983b) , allowing rapid clear ance of the label by the vascular space. However, valine and isoleucine have a significantly lower blood-brain barrier (BBB) permeability than leu cine (Oldendorf, 197 1) and constitute a lower brain protein content (Bodsch and Hossmann, 1983) , which may compromise the counting statistics and signal-to-noise ratio when using these tracers. This is reflected by rat brain data for L-e4C]valine (Kiri kae et aI., 1988) , where rate constants and rate of valine incorporation into protein are less than those for L-[1_14C]leucine in rat brain (Hawkins et aI., 1989) . The [14C-guanido]arginine model is also mathematically identical to the transaminase limited model for L-[1-14C]leucine (Pardridge, 1983) , but like isoleucine and valine, arginine suffers from lower BBB permeability (Oldendorf, 197 1) and low brain protein content (Keen, unpublished observa tions) .
An examination of reported leucine net influx data for the rat brain was done to determine if it could support the sum of leucine fluxes into protein and oxidative pathways presented in our biochem ical compartmental model (Fig. 9) . Unidirectional leucine influx into the rat brain has been reported to be 17 nmollminlg (Bodsch and Hossmann, 1983) , calculated from a modification of the general flux equation (Gjedde and Rasmussen, 1980) . This ap pears to be consistent with our proposed model (Fig. 9) requiring a leucine influx of at least 6.9 nmollmin/g to feed the leucine oxidative (3.7 nmollmin/g) and protein synthesis (3.2 nmollmin/g) pathways. A reported single-pass uptake of leucine of 6.6 nmollmin/g into the rat brain calculated by the Michaelis-MentenlBUI method of Pardridge (1983) is in good approximation to the sum of measured protein synthesis and oxidation flux values pre sented in this work.
Leucine influx is controlled by the BBB neutral amino acid transport (Pardridge, 1977 (Pardridge, , 1983 . Since the total concentration of all of the competing neu tral amino acids (NAA) (>8 amino acids totaling approximately 1.5 mM in rat) (Sage et aI., 198 1) is well above the Km of transport (approximately 0.15 mM) (Pardridge, 1977 (Pardridge, , 1983 Sage et aI., 198 1) , the NAA transport is normally saturated. Under these conditions, the percent change of transport rate of an individual amino acid would be inversely proportional to the percent change in the total level of all NAAs. On the other hand, when total NAA levels approach the Km of transport (nonsaturating conditions) (Pincus and Barry, 1987) , the change of leucine transport rate would be proportional to changes in leucine plasma concentration and insen sitive to the total concentration of all of the NAAs.
Leucine branching into oxidation or protein in corporation pathways from a common compart ment (LEUa compartment) is dependent on three factors that determine the velocity of any enzyme catalyzed reaction: (a) substrate concentration; (b) enzyme concentration; and (c) kca/Km of the en zyme (Fersht, 1985) . Relevant factors affecting the protein synthesis/oxidation branching ratio of leu cine have been reviewed elsewhere (Keen, 1988) . Protein synthesis and glycolysis (normal states) in the brain are thought to be examples of enzyme limited pathways because the intracellular precur sor concentrations are larger than the Km of the rate-limiting enzyme (Pardridge, 1983; Keen, 1988) .
Moreover, Km 's of the rate-limiting step in reac tions involved in the outward transport and oxida tion of leucine are about 22,000 and 500 J.LM, respec tively (Ames et aI., 1976; Parks et aI., 1976) , indi cating that these pathways are substrate-limited. Thus, at low intracellular leucine levels, branching into protein synthesis would predominate (Parks et aI., 1976) while outward flux and oxidation would increase in proportion to leucine availability (Parks et aI., 1976) , which supports metabolic strategies to reduce leucine oxidation for in vivo determination of protein synthesis with PET (Phelps et aI., 1984 (Phelps et aI., , 1985 .
In summary, (a) the leucine incorporation rate in whole rat brain (CPSR) from an exogenous leucine J Cereb Blood Flow Metab, Vol. 9, No . 4, 1989 source based on direct measurement of leucyl tRNA as precursor was determined to be 3.2 nmol/min/g of brain. (b) The time integral of leucine SA in plasma represented the undiluted time inte gral of leucyl-tRNA (precursor) specific activity used to determine CPSR from an exogenous leucine source. (c) Free leucine, leucyl-tRNA, and KIC tis sue compartments, communicating directly with plasma, and separate secondary free leucine, leucyl-tRNA, and KIC tissue compartments com posed of unlabeled leucine from proteolysis, exist in the brain. (d) Exogenous leucine flux into protein and oxidative pathways in the brain is approxi mately equal in the fed conscious adult rat. (e) Leu cine oxidative flux in the brain is transaminase limited. (f) These biochemical data are used to structure and validate mathematical compartmental models to estimate rates of leucine incorporation in brain proteins in humans from an exogenous leucine source, using easily measured external parameters and PET as described in the accompanying paper (Hawkins et aI., 1989) .
